Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astodrimer - Starpharma

X
Drug Profile

Astodrimer - Starpharma

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; Betadine BV; BETADINE BV Gel; Betafem BV; BRI-7013; Fleurstat BVgel; SPL-7013; VIRALEZE; Viraleze; VivaGel; VivaGel®BV

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomolecular Research Institute
  • Developer Aspen Pharmacare; Starpharma; The Scripps Research Institute
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bacterial vaginosis; COVID 2019 infections
  • Phase I/II Herpes simplex virus infections; HIV infections
  • Preclinical Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome
  • No development reported Conjunctivitis; Human papillomavirus infections; Zika virus infection

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In volunteers) in Australia (Intranasal, Spray)
  • 12 Jun 2023 Starpharma plans to launch astodrimer for Covid-2019 infection in Malaysia
  • 05 Jun 2023 Registered for COVID-2019 infections in Malaysia (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top